Literature DB >> 2109297

Tissue plasminogen activator for postvitrectomy fibrin formation.

G J Jaffe1, G W Abrams, G A Williams, D P Han.   

Abstract

The authors injected 25 micrograms of recombinant tissue plasminogen activator (tPA) into the anterior chamber or vitreous cavity of 23 eyes of 22 patients with severe intraocular fibrin formation that developed after vitrectomy surgery for complicated cases of proliferative vitreoretinopathy (PVR) (13 eyes), diabetic traction retinal detachment (TRD) (7 eyes), or endophthalmitis (3 eyes). Tissue plasminogen activator injected an average (+/- standard deviation) of 73 +/- 63 hours after vitrectomy surgery resulted in complete fibrinolysis in 21 of 23 eyes and partial fibrinolysis in one eye. The mean time to fibrin resolution was 3.0 +/- 1.0 hours. Four eyes required repeat tPA injection for recurrent fibrin formation; repeat injection resulted in complete fibrinolysis in each case. The mean follow-up duration after tPA administration was 6 months. At the final follow-up examination, the retina was totally attached in 18 of 23 eyes and was partially attached in 2. Visual acuity improved in 12 eyes (52%); it was at least 20/400 in 8. Complications of tPA injection included hyphema (2 patients) and corneal stromal thickening (2 patients). Mild, transient, periocular pain that was easily managed with non-narcotic analgesia developed in three patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109297     DOI: 10.1016/s0161-6420(90)32618-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

1.  Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.

Authors:  A Glacet-Bernard; D Kuhn; A K Vine; H Oubraham; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

3.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

Review 4.  Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.

Authors:  G A Stern
Journal:  Trans Am Ophthalmol Soc       Date:  1993

5.  A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy.

Authors:  R Gary Lane; J Michael Jumper; Ma'an A Nasir; Mathew W MacCumber; Brooks W McCuen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-03       Impact factor: 3.117

6.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

Review 7.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

8.  Management of postvitrectomy diabetic vitreous hemorrhage with volume homeostatic fluid-fluid exchanger.

Authors:  Wen-Chuan Wu; Jen-Yu Chen; Ya-Chi Chen; Yo-Chen Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

9.  Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.

Authors:  Takuhiro Yamamoto; Motohiro Kamei; Paradee Kunavisarut; Mihoko Suzuki; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-25       Impact factor: 3.117

10.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.